{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:01:20Z","timestamp":1784588480342,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"30","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA296671-01"],"award-info":[{"award-number":["R21CA296671-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA279916-01A1"],"award-info":[{"award-number":["R21 CA279916-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers because it is typically detected at an advanced stage, progresses rapidly, and resists current therapies. Consequently, early diagnostic biomarkers and novel therapeutic targets are urgently needed. Epithelial Cell Transforming Sequence 2 (ECT2) is a Rho family guanine nucleotide exchange factor that was originally identified as an oncoprotein and later shown to regulate cytokinesis. Here, we evaluated ECT2 expression in human PDAC and its functional requirement for transformed growth and tumorigenicity. We found that ECT2 expression is elevated early in PDAC tumorigenesis, remains high throughout progression, and correlates with poor patient survival. Furthermore, a significant pool of ECT2 is mis-localized in the cytoplasm of PDAC cells. Knockdown of ECT2 inhibited 3D-transformed growth, invasion, and in vivo tumor formation while having little impact on PDAC cell cytokinesis. Mechanistically, we found that ECT2 is required for activation of Rac1 and RhoA and downstream MEK\/ERK and ROCK signaling, respectively. Consistent with these findings, analyses of PDAC patient datasets revealed a strong association between ECT2 expression and Rho GTPase as well as MEK\/ERK and ROCK pathway signatures. Finally, genetic or pharmacologic targeting of ECT2 signaling enhanced PDAC cell sensitivity to MEK inhibition. Taken together, our data identify ECT2 as an early driver of PDAC transformation and highlight it as a promising therapeutic target.<\/jats:p>","DOI":"10.1038\/s41388-026-03860-3","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:18:18Z","timestamp":1781867898000},"page":"3053-3068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early induction of the Rho-GEF ECT2 drives MEK\/ERK oncogenic signaling in pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"45","author":[{"given":"Dania","family":"Al-Qasrawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3178-7098","authenticated-orcid":false,"given":"Nayya N.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Argo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0319-9994","authenticated-orcid":false,"given":"Alicia K.","family":"Fleming Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prita","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaya Y.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla C.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murli","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Storz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6378-3469","authenticated-orcid":false,"given":"Verline","family":"Justilien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"3860_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"3860_CR2","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.","journal-title":"PLoS Med"},{"key":"3860_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501.","journal-title":"Nature"},{"key":"3860_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pharmthera.2016.09.003","volume":"168","author":"KM Mann","year":"2016","unstructured":"Mann KM, Ying H, Juan J, Jenkins NA, Copeland NG. KRAS-related proteins in pancreatic cancer. Pharmacol Ther. 2016;168:29\u201342.","journal-title":"Pharmacol Ther"},{"key":"3860_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21736-w","volume":"12","author":"I Ischenko","year":"2021","unstructured":"Ischenko I, D\u2019Amico S, Rao M, Li J, Hayman MJ, Powers S, et al. KRAS drives immune evasion in a genetic model of pancreatic cancer. Nat Commun. 2021;12:1482.","journal-title":"Nat Commun"},{"key":"3860_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17:153\u201368.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3860_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","volume":"39","author":"KL Bryant","year":"2014","unstructured":"Bryant KL, Mancias JD, Kimmelman AC, Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends Biochem Sci. 2014;39:91\u2013100.","journal-title":"Trends Biochem Sci"},{"key":"3860_CR8","doi-asserted-by":"crossref","unstructured":"Soriano O, Alcon-Perez M, Vicente-Manzanares M, Castellano E. The crossroads between RAS and RHO signaling pathways in cellular transformation, motility and contraction. Genes. 2021;12:819.","DOI":"10.3390\/genes12060819"},{"key":"3860_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1053\/j.gastro.2014.08.032","volume":"147","author":"CY Wu","year":"2014","unstructured":"Wu CY, Carpenter ES, Takeuchi KK, Halbrook CJ, Peverley LV, Bien H, et al. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. Gastroenterology. 2014;147:1405\u201316 e1407.","journal-title":"Gastroenterology"},{"key":"3860_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113042","volume":"42","author":"OL Gutierrez-Ruiz","year":"2023","unstructured":"Gutierrez-Ruiz OL, Johnson KM, Krueger EW, Nooren RE, Cruz-Reyes N, Heppelmann CJ, et al. Ectopic expression of DOCK8 regulates lysosome-mediated pancreatic tumor cell invasion. Cell Rep. 2023;42:113042.","journal-title":"Cell Rep"},{"key":"3860_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ccr.2004.11.024","volume":"7","author":"ME Fernandez-Zapico","year":"2005","unstructured":"Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 2005;7:39\u201349.","journal-title":"Cancer Cell"},{"key":"3860_CR12","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1038\/onc.2013.362","volume":"33","author":"DR Cook","year":"2014","unstructured":"Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene. 2014;33:4021\u201335.","journal-title":"Oncogene"},{"key":"3860_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ccell.2016.12.010","volume":"31","author":"V Justilien","year":"2017","unstructured":"Justilien V, Ali SA, Jamieson L, Yin N, Cox AD, Der CJ, et al. Ect2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma. Cancer Cell. 2017;31:256\u201369.","journal-title":"Cancer Cell"},{"key":"3860_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03450-z","volume":"12","author":"D Xu","year":"2021","unstructured":"Xu D, Wang Y, Wu J, Zhang Z, Chen J, Xie M, et al. ECT2 overexpression promotes the polarization of tumor-associated macrophages in hepatocellular carcinoma via the ECT2\/PLK1\/PTEN pathway. Cell Death Dis. 2021;12:162.","journal-title":"Cell Death Dis"},{"key":"3860_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/1947601913514851","volume":"4","author":"LP Huff","year":"2013","unstructured":"Huff LP, Decristo MJ, Trembath D, Kuan PF, Yim M, Liu J, et al. The role of Ect2 nuclear rhogef activity in ovarian cancer cell transformation. Genes Cancer. 2013;4:460\u201375.","journal-title":"Genes Cancer"},{"key":"3860_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/0008-5472.CAN-20-4218","volume":"82","author":"DR Cook","year":"2022","unstructured":"Cook DR, Kang M, Martin TD, Galanko JA, Loeza GH, Trembath DG, et al. Aberrant expression and subcellular localization of ECT2 drives colorectal cancer progression and growth. Cancer Res. 2022;82:90\u2013104.","journal-title":"Cancer Res"},{"key":"3860_CR17","first-page":"533","volume":"7","author":"ML Zhang","year":"2008","unstructured":"Zhang ML, Lu S, Zhou L, Zheng SS. Correlation between ECT2 gene expression and methylation change of ECT2 promoter region in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2008;7:533\u20138.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"3860_CR18","doi-asserted-by":"publisher","first-page":"G380","DOI":"10.1152\/ajpgi.00185.2020","volume":"320","author":"C Li","year":"2021","unstructured":"Li C, Peng Z, Wang Y, Lam G, Nissen N, Tang J, et al. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis. Am J Physiol Gastrointest Liver Physiol. 2021;320:G380\u2013G395.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3860_CR19","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1158\/0008-5472.CAN-09-2684","volume":"70","author":"ML Scotti","year":"2010","unstructured":"Scotti ML, Bamlet WR, Smyrk TC, Fields AP, Murray NR. Protein kinase C\u03b9 is required for pancreatic cancer cell transformed growth and tumorigenesis. Cancer Res. 2010;70:2064\u201374.","journal-title":"Cancer Res"},{"key":"3860_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55043-x","volume":"15","author":"LI Bastea","year":"2024","unstructured":"Bastea LI, Liu X, Fleming AK, Pandey V, Doppler H, Edenfield BH, et al. Coxsackievirus and adenovirus receptor expression facilitates enteroviral infections to drive the development of pancreatic cancer. Nat Commun. 2024;15:10547.","journal-title":"Nat Commun"},{"key":"3860_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk0775","volume":"384","author":"JA Klomp","year":"2024","unstructured":"Klomp JA, Klomp JE, Stalnecker CA, Bryant KL, Edwards AC, Drizyte-Miller K, et al. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers. Science. 2024;384:eadk0775.","journal-title":"Science"},{"key":"3860_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq5931","volume":"14","author":"N Yin","year":"2022","unstructured":"Yin N, Liu Y, Weems C, Shreeder B, Lou Y, Knutson KL, et al. Protein kinase Ciota mediates immunosuppression in lung adenocarcinoma. Sci Transl Med. 2022;14:eabq5931.","journal-title":"Sci Transl Med"},{"key":"3860_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1083\/jcb.200605022","volume":"174","author":"M Yanagisawa","year":"2006","unstructured":"Yanagisawa M, Anastasiadis PZ. p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness. J Cell Biol. 2006;174:1087\u201396.","journal-title":"J Cell Biol"},{"key":"3860_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1158\/2767-9764.CRC-22-0425","volume":"3","author":"KM Meneses","year":"2023","unstructured":"Meneses KM, Pandya P, Lindemann JA, Al-Qasrawi DS, Argo RA, Weems CM, et al. RAB27B drives a cancer stem cell phenotype in NSCLC cells through enhanced extracellular vesicle secretion. Cancer Res Commun. 2023;3:607\u201320.","journal-title":"Cancer Res Commun"},{"key":"3860_CR25","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1038\/onc.2009.217","volume":"28","author":"V Justilien","year":"2009","unstructured":"Justilien V, Fields AP. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation. Oncogene. 2009;28:3597\u2013607.","journal-title":"Oncogene"},{"key":"3860_CR26","doi-asserted-by":"publisher","first-page":"31109","DOI":"10.1074\/jbc.M505402200","volume":"280","author":"RP Regala","year":"2005","unstructured":"Regala RP, Weems C, Jamieson L, Copland JA, Thompson EA, Fields AP. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem. 2005;280:31109\u201315.","journal-title":"J Biol Chem"},{"key":"3860_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1083\/jcb.147.5.921","volume":"147","author":"T Tatsumoto","year":"1999","unstructured":"Tatsumoto T, Xie X, Blumenthal R, Okamoto I, Miki T. Human ECT2 is an exchange factor for Rho GTPases, phosphorylated in G2\/M phases, and involved in cytokinesis. J Cell Biol. 1999;147:921\u20138.","journal-title":"J Cell Biol"},{"key":"3860_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ajpath.2012.04.011","volume":"181","author":"A Weeks","year":"2012","unstructured":"Weeks A, Okolowsky N, Golbourn B, Ivanchuk S, Smith C, Rutka JT. ECT2 and RASAL2 mediate mesenchymal-amoeboid transition in human astrocytoma cells. Am J Pathol. 2012;181:662\u201374.","journal-title":"Am J Pathol"},{"key":"3860_CR29","doi-asserted-by":"crossref","unstructured":"Justilien V, Lewis KC, Murray NR, Fields AP. Oncogenic Ect2 signaling regulates rRNA synthesis in NSCLC. Small GTPases. 2017;10:388\u201394.","DOI":"10.1080\/21541248.2017.1335274"},{"key":"3860_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/dvdy.24505","volume":"247","author":"H Ungefroren","year":"2018","unstructured":"Ungefroren H, Witte D, Lehnert H. The role of small GTPases of the Rho\/Rac family in TGF-beta-induced EMT and cell motility in cancer. Dev Dyn. 2018;247:451\u201361.","journal-title":"Dev Dyn"},{"key":"3860_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1152\/physrev.00045.2020","volume":"102","author":"E Crosas-Molist","year":"2022","unstructured":"Crosas-Molist E, Samain R, Kohlhammer L, Orgaz JL, George SL, Maiques O, et al. Rho GTPase signaling in cancer progression and dissemination. Physiol Rev. 2022;102:455\u2013510.","journal-title":"Physiol Rev"},{"key":"3860_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537\u201349.","journal-title":"Nat Rev Cancer"},{"key":"3860_CR33","doi-asserted-by":"crossref","unstructured":"Cicenas J, Zalyte E, Rimkus A, Dapkus D, Noreika R, Urbonavicius S. JNK, p38, ERK, and SGK1 inhibitors in cancer. Cancers. 2017;10:1.","DOI":"10.3390\/cancers10010001"},{"key":"3860_CR34","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1038\/onc.2010.95","volume":"29","author":"Z Wang","year":"2010","unstructured":"Wang Z, Pedersen E, Basse A, Lefever T, Peyrollier K, Kapoor S, et al. Rac1 is crucial for Ras-dependent skin tumor formation by controlling Pak1-Mek-Erk hyperactivation and hyperproliferation in vivo. Oncogene. 2010;29:3362\u201373.","journal-title":"Oncogene"},{"key":"3860_CR35","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.cellsig.2007.01.018","volume":"19","author":"ER Park","year":"2007","unstructured":"Park ER, Eblen ST, Catling AD. MEK1 activation by PAK: a novel mechanism. Cell Signal. 2007;19:1488\u201396.","journal-title":"Cell Signal"},{"key":"3860_CR36","doi-asserted-by":"publisher","first-page":"23934","DOI":"10.1074\/jbc.270.41.23934","volume":"270","author":"S Zhang","year":"1995","unstructured":"Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, et al. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem. 1995;270:23934\u20136.","journal-title":"J Biol Chem"},{"key":"3860_CR37","doi-asserted-by":"publisher","first-page":"e29846","DOI":"10.4161\/sgtp.29846","volume":"5","author":"L Julian","year":"2014","unstructured":"Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846.","journal-title":"Small GTPases"},{"key":"3860_CR38","doi-asserted-by":"crossref","unstructured":"Guan G, Cannon RD, Coates DE, Mei L. Effect of the rho-kinase\/ROCK signaling pathway on cytoskeleton components. Genes. 2023;14:272.","DOI":"10.3390\/genes14020272"},{"key":"3860_CR39","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/sj.onc.1210790","volume":"27","author":"S Zhu","year":"2008","unstructured":"Zhu S, Korzh V, Gong Z, Low BC. RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek\/Erk pathway. Oncogene. 2008;27:1580\u20139.","journal-title":"Oncogene"},{"key":"3860_CR40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/bioinformatics\/btn635","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Ung CY, Ma XH, Li BW, Low BC, Cao ZW, et al. Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1. Bioinformatics. 2009;25:358\u201364.","journal-title":"Bioinformatics"},{"key":"3860_CR41","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/sj.onc.1202022","volume":"17","author":"M Zohar","year":"1998","unstructured":"Zohar M, Teramoto H, Katz BZ, Yamada KM, Gutkind JS. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. Oncogene. 1998;17:991\u20138.","journal-title":"Oncogene"},{"key":"3860_CR42","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1128\/MCB.17.3.1324","volume":"17","author":"JK Westwick","year":"1997","unstructured":"Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, et al. Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol. 1997;17:1324\u201335.","journal-title":"Mol Cell Biol"},{"key":"3860_CR43","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3892\/ijo.2017.4093","volume":"51","author":"GA Cardama","year":"2017","unstructured":"Cardama GA, Gonzalez N, Maggio J, Menna PL, Gomez DE. Rho GTPases as therapeutic targets in cancer (Review). Int J Oncol. 2017;51:1025\u201334.","journal-title":"Int J Oncol"},{"key":"3860_CR44","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.1074\/jbc.M110.196113","volume":"286","author":"V Justilien","year":"2011","unstructured":"Justilien V, Jameison L, Der CJ, Rossman KL, Fields AP. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation. J Biol Chem. 2011;286:8149\u201357.","journal-title":"J Biol Chem"},{"key":"3860_CR45","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008\u201320.","journal-title":"Lancet"},{"key":"3860_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1053\/j.gastro.2016.05.006","volume":"151","author":"R Gruber","year":"2016","unstructured":"Gruber R, Panayiotou R, Nye E, Spencer-Dene B, Stamp G, Behrens A. YAP1 and TAZ control pancreatic cancer initiation in mice by direct up-regulation of JAK-STAT3 signaling. Gastroenterology. 2016;151:526\u201339.","journal-title":"Gastroenterology"},{"key":"3860_CR47","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-23-2994","volume":"83","author":"AC Edwards","year":"2023","unstructured":"Edwards AC, Stalnecker CA, Jean Morales A, Taylor KE, Klomp JE, Klomp JA, et al. TEAD inhibition overcomes YAP1\/TAZ-driven primary and acquired resistance to KRASG12C inhibitors. Cancer Res. 2023;83:4112\u201329.","journal-title":"Cancer Res"},{"key":"3860_CR48","doi-asserted-by":"publisher","first-page":"8089","DOI":"10.1158\/0008-5472.CAN-07-2300","volume":"67","author":"JL Kissil","year":"2007","unstructured":"Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, et al. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Res. 2007;67:8089\u201394.","journal-title":"Cancer Res"},{"key":"3860_CR49","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.gastro.2011.04.043","volume":"141","author":"I Heid","year":"2011","unstructured":"Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM, et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology. 2011;141:719\u201330. 730 e711-717.","journal-title":"Gastroenterology"},{"key":"3860_CR50","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.18632\/oncotarget.13152","volume":"8","author":"OA Kent","year":"2017","unstructured":"Kent OA, Sandi MJ, Burston HE, Brown KR, Rottapel R. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer. Oncotarget. 2017;8:4484\u20134500.","journal-title":"Oncotarget"},{"key":"3860_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1091\/mbc.e07-04-0370","volume":"19","author":"M Kanada","year":"2008","unstructured":"Kanada M, Nagasaki A, Uyeda TQ. Novel functions of Ect2 in polar lamellipodia formation and polarity maintenance during \u201cContractile ring-independent\u201d cytokinesis in adherent cells. Mol Biol Cell. 2008;19:8\u201316.","journal-title":"Mol Biol Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03860-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03860-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:02:14Z","timestamp":1784584934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03860-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":51,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2026,8,11]]}},"alternative-id":["3860"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03860-3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The use of human pancreatic tissue specimens and associated clinical data was approved by the Mayo Clinic Institutional Review Board (IRB Protocol No. 24-009702). Informed consent was obtained from all participants. All animal studies were approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC Protocol No. A00006924-22) and were conducted in accordance with institutional guidelines for the care and use of laboratory animals. No identifiable images of human participants were included in this study.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}